RxDoctor Payments Data

Hilda Metjian, MD

Pulmonary Disease · Denver, CONPI 1952513236

Payments from drug & device makers

$2,893in general payments, 2019–2025

Across 138 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$459
  • Genentech USA, Inc.$377
  • AstraZeneca$298
  • GSK$288
  • Alnylam Pharmaceuticals Inc.$223
  • Insmed, Inc.$198
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$2,887100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,893 in reported general payments places this provider in the 65th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$37,091
Medicare patients
182
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$61,651
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr65$33,777
Breo ElliptaFluticasone/Vilanterol49$24,134
SymbicortBudesonide/Formoterol Fumarate50$17,046
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,340
Advair HfaFluticasone Propion/Salmeterol17$6,767
Arnuity ElliptaFluticasone Furoate18$5,888
DuleraMometasone/Formoterol16$4,933
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,882
Albuterol Sulfate HfaAlbuterol Sulfate58$1,133
Azithromycin38$427
Montelukast Sodium22$319
Omeprazole35$286
Famotidine22$152
Prednisone32$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$288$125,450204 claims
AstraZenecaSymbicort, Breztri Aerosphere$298$28,38664 claims
MerckDulera$47$4,93316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →